Privium Fund Management B.V. Grows Stock Position in ProQR Therapeutics N.V. $PRQR

Privium Fund Management B.V. raised its stake in ProQR Therapeutics N.V. (NASDAQ:PRQR) by 0.2% in the second quarter, Holdings Channel reports. The fund owned 4,997,562 shares of the biopharmaceutical company’s stock after purchasing an additional 11,929 shares during the quarter. ProQR Therapeutics accounts for approximately 2.2% of Privium Fund Management B.V.’s investment portfolio, making the stock its 10th largest holding. Privium Fund Management B.V.’s holdings in ProQR Therapeutics were worth $10,045,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in PRQR. Vontobel Holding Ltd. increased its position in ProQR Therapeutics by 76.5% during the 2nd quarter. Vontobel Holding Ltd. now owns 63,979 shares of the biopharmaceutical company’s stock worth $131,000 after purchasing an additional 27,722 shares in the last quarter. Jane Street Group LLC grew its stake in shares of ProQR Therapeutics by 699.3% during the first quarter. Jane Street Group LLC now owns 91,120 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 79,720 shares during the last quarter. Affinity Asset Advisors LLC increased its holdings in shares of ProQR Therapeutics by 16.3% during the first quarter. Affinity Asset Advisors LLC now owns 3,284,512 shares of the biopharmaceutical company’s stock worth $4,368,000 after buying an additional 459,512 shares in the last quarter. Walleye Capital LLC lifted its stake in shares of ProQR Therapeutics by 11.6% in the 1st quarter. Walleye Capital LLC now owns 503,564 shares of the biopharmaceutical company’s stock valued at $670,000 after acquiring an additional 52,261 shares during the last quarter. Finally, Aberdeen Group plc acquired a new stake in shares of ProQR Therapeutics during the 1st quarter valued at $2,461,000. 32.65% of the stock is currently owned by institutional investors and hedge funds.

ProQR Therapeutics Price Performance

ProQR Therapeutics stock opened at $3.05 on Tuesday. The stock’s 50 day moving average is $2.26 and its 200 day moving average is $1.97. ProQR Therapeutics N.V. has a one year low of $1.07 and a one year high of $4.38. The firm has a market cap of $320.89 million, a P/E ratio of -6.63 and a beta of 0.23.

ProQR Therapeutics (NASDAQ:PRQR) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.06). ProQR Therapeutics had a negative return on equity of 61.25% and a negative net margin of 238.52%.The firm had revenue of $4.33 million for the quarter, compared to the consensus estimate of $5.01 million. Equities analysts anticipate that ProQR Therapeutics N.V. will post -0.31 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have issued reports on PRQR shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $8.00 target price on shares of ProQR Therapeutics in a report on Friday, June 27th. Chardan Capital reaffirmed a “buy” rating and issued a $4.00 price objective on shares of ProQR Therapeutics in a research note on Friday, August 8th. JMP Securities reiterated a “market outperform” rating and issued a $8.00 price objective on shares of ProQR Therapeutics in a report on Friday, June 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of ProQR Therapeutics in a report on Wednesday, October 8th. Finally, Zacks Research cut shares of ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Wednesday, October 15th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $8.00.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).